$100 Million

NuCana

Initial Public Offering

Bookrunner, September 2017

NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying the Company’s phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. Utilizing NuCana’s proprietary ProTide technology, the Company is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The Company is currently developing three product candidates including lead candidate Acelarin.